Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$36.24 USD
+2.62 (7.79%)
Updated May 1, 2024 04:00 PM ET
After-Market: $36.24 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Brokerage Reports
Kymera Therapeutics, Inc. [KYMR]
Reports for Purchase
Showing records 1 - 20 ( 32 total )
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Kymeras KT-294 (TYK-2 Degrader) Continues to Build a Differentiated Narrative; Reiterate Buy and PT Up to $46
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Kymeras KT-293 (TYK-2 Degrader) Continues to Build a Differentiated Narrative
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Newly Unveiled Immunology Programs Attractive for Potential Partnership Deals
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PK, PD, and Safety Data Allow Wider Therapeutic Window for KT-333; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KYMR 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial PoC Data From STAT3 and MDM2 Programs Supports Further Development; Reiterate Buy and PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KT-253s Superiority to SMIs Supports Degrader Approach to Target MDM2; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expectations for KT-413s ICML Data Readout; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Invite: Getting Under the Skin in HS & PsA
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KT-253 is an Ambitious Program with Potential for Broad Franchise Opportunities; Reit. Buy and $85 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sanofi Puts Skin in the Game¯Thoughts on KT-474 Data Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cereblon Dumps Thalidomide for Better Degrons¯Takeaways From The 5th Targeted Protein Degradation Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KT-333¯Drugging the Undruggable STAT3; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EADV Data Stresses the Importance of Scaffolding Function of IRAK4, Pending Biomarker Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Setting Appropriate Expectations for KT-474s Part C Study; Reiterate Buy and $85 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Considerations for Kymeras KT-474 Patient Study Readout in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MDM2 Degrader KT-253 Open Broad Franchise Opportunities For Kymera - Our Thoughts on AACR Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KT-474''s Proof of Biology Data in 2H22 Is All About Safety and Cytokine Suppression
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KT-474 Data Places Kymera as a TPD Leader in the Inflammatory Disease Space
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A